What is DxTerity?
DxTerity specializes in pioneering RNA-based diagnostics tailored for autoimmune diseases. The company provides precision testing solutions designed to empower individuals in managing their health proactively. By focusing on the intricate biological mechanisms of autoimmune conditions, DxTerity equips healthcare providers with more accurate diagnostic and therapeutic tools. Leveraging patented technologies, the firm is committed to making cutting-edge precision medicine accessible and affordable, with an emphasis on enhancing patient well-being through at-home genomic monitoring. Their ongoing involvement in clinical studies further solidifies their dedication to advancing the understanding and treatment of autoimmune diseases.
How much funding has DxTerity raised?
DxTerity has raised a total of $4.5M across 4 funding rounds:
Private Equity
$790K
Debt
$2.6M
Debt
$350K
Debt
$794K
Private Equity (2009): $790K, investors not publicly disclosed
Debt (2012): $2.6M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Debt (2021): $794K featuring PPP
Key Investors in DxTerity
PPP
Public-Private Partnership
What's next for DxTerity?
With a substantial enterprise-level funding context, DxTerity is strategically positioned for significant scaling and further innovation in the precision diagnostics sector. The recent major strategic investment signals strong confidence from backers in the company's trajectory and its potential to disrupt the autoimmune disease market. This capital will likely fuel advancements in their patented RNA-based diagnostic technologies, expand clinical study participation, and enhance their at-home genomic monitoring capabilities. The company's focus on affordability and precision medicine suggests a continued push towards broader market penetration and strategic partnerships within the healthcare ecosystem.
See full DxTerity company page
